Advertisement
Organisation › Details
Revolution Medicines Inc. (RVMD)
REVOLUTION Medicines is a clinical-stage leader in the discovery and development of precise small molecule therapeutics designed to translate frontier oncology targets within notorious pathways to outsmart cancer. It possesses industry-leading oncology drug discovery capabilities built upon deep scientific knowledge of the biology of cancer pathways and innovative, proprietary technologies that enable the creation of small molecules that target atypical drug binding sites. The company’s pipeline includes RMC-4630, a clinical-stage drug candidate that selectively inhibits the activity of SHP2. Additionally, the company is developing a broad portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related PI3K/AKT/mTOR cascade. These include multiple mutant RAS proteins, with its KRASG12C(GTP) program currently in lead optimization; 4EBP1/mTORC1, with a development candidate, RMC-5552, currently advancing into IND-enabling studies; and SOS1, a discovery-stage program. *
Start | 2018-07-18 existent | |
Industry | SHP2 inhibitor | |
Industry 2 | drug discovery | |
Person | Goldsmith, Mark A. (Revolution Medicines 201807 CEO) | |
Region | Redwood City, CA | |
Country | United States (USA) | |
Street | 700 Saginaw Drive | |
City | 94063 Redwood City, CA | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Revolution Medicines, Inc.. (7/9/19). "Press Release: Revolution Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers". Redwood City, CA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Revolution Medicines Inc. (RVMD)
- [1] Revolution Medicines, Inc.. (7/9/19). "Press Release: Revolution Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers". Redwood City, CA....
- [2] Revolution Medicines, Inc.. (10/16/18). "Press Release: Revolution Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets". Redwood City, CA & Cambridge, MA....
- [3] Revolution Medicines, Inc.. (7/18/18). "Press Release: Sanofi and Revolution Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers". Cambridge, MA & Redwood City, CA....
- [4] Revolution Medicines, Inc.. (4/24/18). "Press Release: Revolution Medicines Raises $56 Million in Series B Financing". Redwood City, CA....
- [5] Warp Drive Bio, Inc.. (10/16/17). "Press Release: Warp Drive Bio Forms Strategic Collaboration to Advance Novel Classes of Antibiotics to Combat Multi-Drug-Resistant Bacterial Infections". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top